Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Nicox Enters into Research Collaboration Agreement with Ironwood Pharma 11
Nicox Enters into Agreement with Ironwood Pharma 12
Ironwood Pharma Enters into Co-Promotion Agreement with Allergan 13
Ironwood Pharma And Protagonist Therapeutics Expand Peptide Drug Discovery Collaboration 14
AstraZeneca Enters Into Co-Development Agreement With Ironwood Pharma For Linaclotide 15
Licensing Agreements 17
Synergy Pharma Enters Into Agreement With Ironwood Pharma For Plecanatide 17
Equity Offering 18
Ironwood Pharma Plans to Raise Funds through Public Offering of Securities 18
Ironwood Pharma Raises USD201.3 Million in Public Offering of Shares 19
Ironwood Pharma Completes Partial Exercise Of Underwriter’s Option For Public Offering Of Shares For US$146 Million 21
Ironwood Pharma Completes Public Offering Of Common Stock For US$91 Million 23
Debt Offering 25
Ironwood Pharma Raises USD150 Million in Private Placement of 8.375% Notes Due 2026 25
Ironwood Pharma Raises USD335.7 Million in Private Placement of 2.25% Notes Due 2022 26
Ironwood Pharma Completes Private Placement Of Notes Due 2024 For US$175 Million 27
Ironwood Pharmaceuticals Inc – Key Competitors 29
Ironwood Pharmaceuticals Inc – Key Employees 30
Ironwood Pharmaceuticals Inc – Locations And Subsidiaries 31
Head Office 31
Other Locations & Subsidiaries 31
Recent Developments 32
Financial Announcements 32
Aug 06, 2018: Ironwood Pharmaceuticals provides second quarter 2018 investor update 32
May 01, 2018: Ironwood Pharmaceuticals Provides First Quarter 2018 Investor Update 37
Feb 15, 2018: Ironwood Pharmaceuticals Reports Fourth Quarter 2017 Financial Results 39
Nov 02, 2017: Ironwood Pharmaceuticals Provides Third Quarter 2017 Investor Update 42
Aug 03, 2017: Ironwood Pharmaceuticals Provides Second Quarter 2017 Investor Update 47
May 08, 2017: Ironwood Pharmaceuticals Provides First Quarter 2017 Investor Update 49
Feb 21, 2017: Ironwood Pharmaceuticals Provides Fourth Quarter and Full Year 2016 Investor Update 51
Corporate Communications 55
Nov 28, 2017: Ironwood Pharmaceuticals Strengthens Executive Leadership Team 55
Sep 06, 2017: Ironwood Pharmaceuticals Announces Leadership Change 56
Apr 06, 2017: Ironwood Pharmaceuticals Appoints Dr. Christopher Wright as Senior Vice President of Global Development and Chief Development Officer 57
Jan 04, 2017: Ironwood Pharmaceuticals Appoints Amy Schulman to Board of Directors 58
Government and Public Interest 59
May 01, 2018: Ironwood Pharmaceuticals Announces Intent to Separate Soluble Guanylate Cyclase Business from Commercial and Gastrointestinal Business 59
Clinical Trials 61
Jun 21, 2018: Ironwood begins two Phase III trials of IW-3718 61
Jun 05, 2018: Ironwood Pharmaceuticals Presents IW-3718 Data Showing Improvements in Heartburn and Regurgitation Symptoms in Patients with Persistent GERD at Digestive Disease Week 2018 62
May 23, 2018: Ironwood Pharmaceuticals to Highlight Clinical Data for IW-3718 in Persistent Gastroesophageal Reflux Disease (GERD) at Digestive Disease Week 2018 64
Dec 21, 2017: Ironwood Pharmaceuticals Initiates Phase II Clinical Trial of sGC Stimulator IW-1701 in Patients with Sickle Cell Disease 66
Dec 04, 2017: Ironwood Reports Top-line Phase IIa Data for IW-1973 Demonstrating Positive Cardiovascular, Metabolic and Endothelial Effects 67
Jul 20, 2017: Ironwood Pharmaceuticals Reports Positive Top-line Results from IW-3718 Phase IIb Trial in Uncontrolled Gastroesophageal Reflux Disease 69
May 01, 2017: Ironwood Pharmaceuticals to Present New Data for IW-1701 at Digestive Disease Week 2017 71
Mar 09, 2017: Ironwood Pharmaceuticals provides update on key pipeline program IW-1973 at R&D Day 2017 72
Mar 09, 2017: Ironwood Pharmaceuticals provides update on key pipeline program IW-3718 at R&D Day 2017 73
Other Significant Developments 74
May 01, 2018: Allergan and Ironwood Launch Interactive Digital Destination During Irritable Bowel Syndrome (IBS) Awareness Month Designed to Encourage Sufferers to Get Educated and Take Action 74
Jan 08, 2017: Ironwood Pharmaceuticals Demonstrates Strong Execution on Strategy to Build Top-Performing Commercial Biotech 75
Appendix 77
Methodology 77
About GlobalData 77
Contact Us 77
Disclaimer 77
Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Ironwood Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Nicox Enters into Research Collaboration Agreement with Ironwood Pharma 11
Nicox Enters into Agreement with Ironwood Pharma 12
Ironwood Pharma Enters into Co-Promotion Agreement with Allergan 13
Ironwood Pharma And Protagonist Therapeutics Expand Peptide Drug Discovery Collaboration 14
AstraZeneca Enters Into Co-Development Agreement With Ironwood Pharma For Linaclotide 15
Synergy Pharma Enters Into Agreement With Ironwood Pharma For Plecanatide 17
Ironwood Pharma Plans to Raise Funds through Public Offering of Securities 18
Ironwood Pharma Raises USD201.3 Million in Public Offering of Shares 19
Ironwood Pharma Completes Partial Exercise Of Underwriter's Option For Public Offering Of Shares For US$146 Million 21
Ironwood Pharma Completes Public Offering Of Common Stock For US$91 Million 23
Ironwood Pharma Raises USD150 Million in Private Placement of 8.375% Notes Due 2026 25
Ironwood Pharma Raises USD335.7 Million in Private Placement of 2.25% Notes Due 2022 26
Ironwood Pharma Completes Private Placement Of Notes Due 2024 For US$175 Million 27
Ironwood Pharmaceuticals Inc, Key Competitors 29
Ironwood Pharmaceuticals Inc, Key Employees 30
Ironwood Pharmaceuticals Inc, Subsidiaries 31
List of Figures
Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9